v3.10.0.1
Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment (Tables)
 12 Months Ended
Dec. 31, 2018
Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]  
Summary of Assets and Liabilities Held For Sale
The amounts associated with the Consumer Healthcare business, as well as other assets classified as held for sale consisted of the following:
 
 
As of December 31,
(MILLIONS OF DOLLARS)
 
2018

 
2017

Assets Held for Sale
 
 
 
 
Cash and cash equivalents
 
$
32

 
$
—

Trade accounts receivable, less allowance for doubtful accounts
 
532

 
—

Inventories
 
538

 
—

Other current assets
 
56

 
—

PP&E
 
675

 
—

Identifiable intangible assets, less accumulated amortization
 
5,763

 
—

Goodwill
 
1,972

 
—

Noncurrent deferred tax assets and other noncurrent tax assets
 
54

 
—

Other noncurrent assets
 
57

 
—

Total Consumer assets held for sale
 
9,678

 
—

Other assets held for sale(a)
 
46

 
12

Assets held for sale
 
$
9,725

 
$
12

 
 
 
 
 
Liabilities Held for Sale
 
 
 
 
 
 
 
 
 
Trade accounts payable
 
$
406

 
$
—

Income taxes payable
 
39

 
—

Accrued compensation and related items
 
93

 
—

Other current liabilities
 
353

 
—

Pension benefit obligations, net
 
39

 
—

Postretirement benefit obligations, net
 
33

 
—

Noncurrent deferred tax liabilities
 
870

 
—

Other noncurrent liabilities
 
56

 
—

Total Consumer liabilities held for sale
 
$
1,890

 
$
—

(a) 
Other assets held for sale consist of PP&E.
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions
The following table provides the amounts and classification of payments (income/(expense)) between us and our collaboration partners:
 
 
Year Ended December 31,
(MILLIONS OF DOLLARS)
 
2018

 
2017

 
2016

Revenues—Revenues(a)
 
$
571

 
$
606

 
$
659

Revenues—Alliance revenues(b)
 
3,838

 
2,927

 
1,746

Total revenues from collaborative arrangements
 
4,409

 
3,533

 
2,405

Cost of sales(c)
 
(296
)
 
(329
)
 
(315
)
Selling, informational and administrative expenses(d)
 
(90
)
 
(54
)
 
(5
)
Research and development expenses(e)
 
162

 
222

 
64

Other income/(deductions)—net(f)
 
281

 
249

 
542

(a) 
Represents sales to our partners of products manufactured by us.
(b) 
Substantially all relates to amounts earned from our partners under co-promotion agreements. The increases in 2018 and 2017 reflect increases in alliance revenues from Eliquis and Xtandi.
(c) 
Primarily relates to amounts paid to collaboration partners for their share of net sales or profits earned in collaboration arrangements where we are the principal in the transaction, and cost of sales associated with inventory purchased from our partners.
(d) 
Represents net reimbursements to our partners for selling, informational and administrative expenses incurred.
(e) 
Primarily relates to upfront payments and pre-approval milestone payments earned by our partners as well as net reimbursements. The upfront and milestone payments were as follows: $50 million in 2018, $15 million in 2017 and $15 million in 2016. Our collaboration with Lilly (see below) also includes reimbursements of $98 million in 2018, $147 million in 2017 and $120 million in 2016.
(f) 
Primarily relates to royalties from our collaboration partners. The decrease in 2017 is due to the October 31, 2016 expiration of our 36 month royalty arrangement on sales of Enbrel in the U.S. and Canada, partially offset by a full year of royalties earned in 2017, versus a partial year in 2016, on Xtandi ex-U.S. sales.